The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients

Journal of Surgical Oncology

Volumn 106, Issue 7, 2012, Pages 872-879

  Ye, Yan Wei ^a   Zhang, Xiefu ^a   Zhou, Ye ^b,c   Wu, Jianghong ^b,c   Zhao, Chunlin ^a   Yuan, Lin ^b,c   Wang, Guojun ^a   Du, Chunyan ^b,c   Wang, Chunmeng ^b,c   Shi, Yingqiang ^b,c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

FGFR4; gastric cancer; immunohistochemical; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MYC PROTEIN; PROTEIN P21; PROTEIN P53;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868356061     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23153     Document Type: Article

References (34)

1. Eswarakumar VP, Lax I, Schlessinger J:, Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-149.
2. Wang J, Stockton DW, Ittmann M:, The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10: 6169-6178.
3. Katoh M:, Genetic alterations of FGF receptors: An emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther 2010; 10: 1375-1379.
4. Ye Y, Shi Y, Zhou Y, et al.: The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol 2010; 12: 3354-3361.
5. Ye YW, Zhou Y, Yuan L, et al.: Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression. Cancer 2011; 117: 5304-5313.
6. Greene FL, Page DL, Fleming ID, et al.: American Joint Committee on Cancer Staging Manual, 6th edition. Philadelphia: Springer; 2002.
7. Thussbas C, Nahrig J, Streit S:, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747-3755.
8. Kwon HC, Roh MS, Oh SY, et al.: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18: 504-509.
9. Al-Moundhri MS, Nirmala V, Al-Hadabi I, et al.: The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: A clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol 2005; 91: 243-252.
10. Kaplan EL, Meier P:, Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
11. Cox DR:, Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
12. Jacquemier J, Adelaide J, Parc P, et al.: Expression of the FGFR1 gene in human breast carcinoma cells. Int J Cancer 1994; 59: 373-378.
13. Leung HY, Gullick WJ, Lemoine NR:, Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 1994; 59: 667-675.
14. Takahashi A, Sasaki H, Kim SJ, et al.: Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun 1999; 257: 855-859.
15. Fenoglio-Preiser CM, Wang J, Stemmermann GN:, TP53 and gastric carcinoma: A review. Hum Mutat 2003; 21: 258-270.
16. Sumiyoshi Y, Kakeji Y, Egashira A, et al.: Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 2006; 12: 5112-5117.
17. Park DI, Yun JW, Park JH, et al.: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379.
18. Konno S, Takebayashi Y, Aiba M, et al.: Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett 2001; 166: 103-111.
19. Kanaji S, Saito H, Tsujitani S, et al.: Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006; 70: 126-133.
20. Suerbaum S, Michetti P:, Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186.
21. Zhang H, Fang DC, Wang RQ, et al.: Effect of Helicobacter pylori infection on expression of Bcl-2 family members in gastric adenocarcinoma. World J Gastroenterol 2004; 10: 227-230.
22. Heng JD, Werness BA, Babb JS, et al.: Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res 1999; 5: 1057-1062.
23. Meijer D, Sieuwerts AM, Look MP, et al.: Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 2008; 15: 101-111.
24. Milano A, Dal Lago L, Sotiriou C, et al.: What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer 2006; 42: 2692-2705.
25. Thussbas C, Nahrig J, Streit S, et al.: FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747-3755.
26. Gowardhan B, Douglas DA, Mathers ME, et al.: Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005; 92: 320-327.
27. Ho HK, Pok S, Streit S, et al.: Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50: 118-127.
28. Adachi Y, Mori M, Maehara Y, et al.: Dukes's classification: A valid prognostic indicator for gastric cancer. Gut 1994; 35: 1368-1371.
29. Begnami MD, Fregnani JH, Nonogaki S, et al.: Evaluation of cell cycle protein expression in gastric cancer: Cyclin B1 expression and its prognostic implication. Hum Pathol 2010; 41: 1120-1127.
30. Carrasco V, Canfrán S, Rodríguez-Franco F, et al.: Canine gastric carcinoma: Immunohistochemical expression of cell cycle proteins (p53, p21, and p16) and heat shock proteins (Hsp27 and Hsp70). Vet Pathol 2011; 48: 322-329.
31. Aoyagi K, Koufuji K, Yano S, et al.: The expression of p53, p21 and TGF beta 1 in gastric carcinoma. Kurume Med J 2003; 50: 1-7.
32. Xie H, Su Q, He X, et al.: Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. World J Gastroenterol 2004; 10: 1125-1131.
33. Mizokami K, Kakeji Y, Oda S, et al.: Relationship of hypoxia-inducible factor 1alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol 2006; 4: 94.
34. Kouraklis G, Katsoulis IE, Theocharis S, et al.: Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma ? Dig Dis Sci 2009; 54: 1015-1020.